IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders

First patient dosed in Phase 3 OVATION 3 Study of IMNN-001 for treatment of newly diagnosed advanced ovarian cancer

Read more at globenewswire.com